164 related articles for article (PubMed ID: 30051651)
1. Intermittent or uneven daily administration of low-dose hydroxyurea is effective in treating children with sickle cell anemia in Angola.
Chambers TM; Kahan S; Camanda JF; Scheurer M; Airewele GE
Pediatr Blood Cancer; 2018 Dec; 65(12):e27365. PubMed ID: 30051651
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
McGann PT; Tshilolo L; Santos B; Tomlinson GA; Stuber S; Latham T; Aygun B; Obaro SK; Olupot-Olupot P; Williams TN; Odame I; Ware RE;
Pediatr Blood Cancer; 2016 Jan; 63(1):98-104. PubMed ID: 26275071
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
[TBL] [Abstract][Full Text] [Related]
5. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
McGann PT; Williams TN; Olupot-Olupot P; Tomlinson GA; Lane A; Luís Reis da Fonseca J; Kitenge R; Mochamah G; Wabwire H; Stuber S; Howard TA; McElhinney K; Aygun B; Latham T; Santos B; Tshilolo L; Ware RE;
Am J Hematol; 2018 Aug; 93(4):537-545. PubMed ID: 29318647
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.
Olupot-Olupot P; Tomlinson G; Williams TN; Tshilolo L; Santos B; Smart LR; McElhinney K; Howard TA; Aygun B; Stuber SE; Lane A; Latham TS; Ware RE
Blood; 2023 Mar; 141(12):1402-1410. PubMed ID: 36375125
[TBL] [Abstract][Full Text] [Related]
8. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
Opoka RO; Ndugwa CM; Latham TS; Lane A; Hume HA; Kasirye P; Hodges JS; Ware RE; John CC
Blood; 2017 Dec; 130(24):2585-2593. PubMed ID: 29051184
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea therapy for sickle cell anemia.
McGann PT; Ware RE
Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
[TBL] [Abstract][Full Text] [Related]
10. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
Power-Hays A; Tomlinson GA; Tshilolo L; Santos B; Williams TN; Olupot-Olupot P; Smart LR; Aygun B; Lane A; Stuber SE; Latham T; Ware RE
Am J Hematol; 2024 Apr; 99(4):625-632. PubMed ID: 38332651
[TBL] [Abstract][Full Text] [Related]
11. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.
Hankins JS; Aygun B; Nottage K; Thornburg C; Smeltzer MP; Ware RE; Wang WC
Medicine (Baltimore); 2014 Dec; 93(28):e215. PubMed ID: 25526439
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens.
Teigen D; Opoka RO; Kasirye P; Nabaggala C; Hume HA; Blomberg B; John CC; Ware RE; Robberstad B
Pharmacoeconomics; 2023 Dec; 41(12):1603-1615. PubMed ID: 37462838
[TBL] [Abstract][Full Text] [Related]
13. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).
Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR
Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea therapy in UK children with sickle cell anaemia: A single-centre experience.
Phillips K; Healy L; Smith L; Keenan R
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28988427
[TBL] [Abstract][Full Text] [Related]
16. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges.
Dexter D; McGann PT
Pharmacotherapy; 2023 May; 43(5):430-441. PubMed ID: 36906823
[TBL] [Abstract][Full Text] [Related]
18. Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine.
Dong M; McGann PT
Clin Pharmacol Ther; 2021 Jan; 109(1):73-81. PubMed ID: 32869281
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
Colombatti R; Palazzi G; Masera N; Notarangelo LD; Bonetti E; Samperi P; Barone A; Perrotta S; Facchini E; Miano M; Del Vecchio GC; Guerzoni ME; Corti P; Menzato F; Cesaro S; Casale M; Rigano P; Forni GL; Russo G; Sainati L;
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28868627
[TBL] [Abstract][Full Text] [Related]
20. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia.
Estepp JH; Winter B; Johnson M; Smeltzer MP; Howard SC; Hankins JS
Pediatr Blood Cancer; 2014 Nov; 61(11):2031-6. PubMed ID: 25132074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
